SCHEMBL4050231

SCHEMBL4050231

[c]1c[nH]c(-c2cc(-c3ccccc3)ccn2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
ASIC3 Q9UHC3 2/20 0.38
TGFBR1 P36897 1/20 0.37
NPY5R Q15761 2/20 0.36
PLAU P00749 1/20 0.36
MTOR P42345 1/20 0.36
ADK P55263 1/20 0.36
NISCH Q9Y2I1 1/20 0.36
SMO Q99835 2/20 0.35
PIM1 P11309 1/20 0.35
NOTUM Q6P988 1/20 0.34
PIK3CA P42336 1/20 0.34
CDK1 P06493 1/20 0.34
MAPKAPK2 P49137 1/20 0.34
MAPKAPK3 Q16644 1/20 0.34
MAPKAPK5 Q8IW41 1/20 0.34
MKNK1 Q9BUB5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4044973 0.88 ASIC3 (0.45) CYP1A2CYP3A4ASIC3TGFBR1NPY5R
SCHEMBL4048566 0.79 ASIC3 (0.46) CYP1A2CYP2C9CYP2C19ASIC3SMO
SCHEMBL4046324 0.78 KMO (0.40) CYP1A2CYP3A4CYP2C9CYP2C19NISCH
SCHEMBL4044219 0.78 KMT2A (0.43) MTORADKNISCHSMO
SCHEMBL2653482 0.76 KDM4E (0.48) CYP1A2NPY5RMTOR
SCHEMBL4041670 0.76 MTOR (0.41) CYP1A2CYP3A4NPY5RMTORADK
SCHEMBL403894 0.75 MTOR (0.43) CYP1A2CYP3A4NPY5RMTORADK
SCHEMBL417290 0.75 ASIC3 (0.54) ASIC3TGFBR1PLAUSMOPIM1
SCHEMBL4043825 0.75 TGFBR1 (0.43) CYP1A2CYP3A4CYP2C9CYP2C19ASIC3
SCHEMBL28116354 0.74 ASIC3 (0.53) ASIC3TGFBR1PLAUNISCHSMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589096-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-09-15 US disclosed
EP-1566384-B1 NOVEL AZOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2009-06-17 EP disclosed
US-20080188507-A1 Novel azole derivatives MSD K.K. (JP) 2008-08-07 US disclosed
US-7365079-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-29 US disclosed
US-20060111380-A1 Novel azole derivatives MSD K.K. (JP) 2006-05-25 US disclosed
EP-1566384-A1 NOVEL AZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188507-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R CYP1A2 333/4885CYP3A4 547/4885CYP2C9 594/4885
US-20060111380-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R CYP1A2 335/4885CYP3A4 601/4885CYP2C9 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.